CN105683183B - 作为rsv抗病毒化合物的经取代的吡啶-哌嗪基类似物 - Google Patents

作为rsv抗病毒化合物的经取代的吡啶-哌嗪基类似物 Download PDF

Info

Publication number
CN105683183B
CN105683183B CN201480043020.5A CN201480043020A CN105683183B CN 105683183 B CN105683183 B CN 105683183B CN 201480043020 A CN201480043020 A CN 201480043020A CN 105683183 B CN105683183 B CN 105683183B
Authority
CN
China
Prior art keywords
compound
alkyl
mmol
hydrogen
evaporated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480043020.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105683183A (zh
Inventor
J.E.G.圭勒蒙特
D.F.A.兰科伊斯
M.M.S.莫特
D.Y.R.拉德奥
X.M.博德雷兹
W.M.A.巴勒曼斯
D.A.E.罗伊曼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of CN105683183A publication Critical patent/CN105683183A/zh
Application granted granted Critical
Publication of CN105683183B publication Critical patent/CN105683183B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201480043020.5A 2013-07-30 2014-07-29 作为rsv抗病毒化合物的经取代的吡啶-哌嗪基类似物 Expired - Fee Related CN105683183B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13178543 2013-07-30
EP13178543.8 2013-07-30
PCT/EP2014/066273 WO2015014836A1 (en) 2013-07-30 2014-07-29 Substituted pyridine-piperazinyl analogues as rsv antiviral compounds

Publications (2)

Publication Number Publication Date
CN105683183A CN105683183A (zh) 2016-06-15
CN105683183B true CN105683183B (zh) 2018-06-22

Family

ID=48874955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480043020.5A Expired - Fee Related CN105683183B (zh) 2013-07-30 2014-07-29 作为rsv抗病毒化合物的经取代的吡啶-哌嗪基类似物

Country Status (10)

Country Link
US (2) US20160168124A1 (enExample)
EP (1) EP3027608B1 (enExample)
JP (1) JP6397912B2 (enExample)
KR (1) KR102297433B1 (enExample)
CN (1) CN105683183B (enExample)
AU (1) AU2014298561B8 (enExample)
CA (1) CA2914762C (enExample)
EA (1) EA027732B1 (enExample)
ES (1) ES2724577T3 (enExample)
WO (1) WO2015014836A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020008061A (es) * 2018-01-31 2020-09-09 Janssen Sciences Ireland Unlimited Co Pirazolopirimidinas sustituidas con cicloalquilo que tienen actividad contra vrs.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
WO2008099210A2 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2011110852A1 (en) * 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2011158039A1 (en) * 2010-06-17 2011-12-22 Respivert Limited Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections
CN102596946A (zh) * 2009-08-05 2012-07-18 港大科桥有限公司 抗病毒化合物及其制备和使用方法
US20130005710A1 (en) * 2009-11-18 2013-01-03 Tetsuya Tsukamoto Aminopyridine derivative

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL147465B1 (en) * 1984-03-26 1989-06-30 Janssen Pharmaceutica Nv Method of obtaining novel pyridazionoamine compounds
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
MY145822A (en) 2004-08-13 2012-04-30 Neurogen Corp Substituted biaryl piperazinyl-pyridine analogues
WO2008008453A1 (en) 2006-07-14 2008-01-17 Schering Corporation Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
EP2149373A1 (en) 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. 5HT7 receptor ligands and compositions comprising the same
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
US20120142701A1 (en) 2010-05-28 2012-06-07 The University Of Hong Kong Compounds and methods for the treatment of proliferative diseases
LT3002278T (lt) * 2011-03-15 2017-06-26 Astellas Pharma Inc. Guanidino junginys

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058876A1 (en) * 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
WO2008099210A2 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
CN102596946A (zh) * 2009-08-05 2012-07-18 港大科桥有限公司 抗病毒化合物及其制备和使用方法
US20130005710A1 (en) * 2009-11-18 2013-01-03 Tetsuya Tsukamoto Aminopyridine derivative
WO2011110852A1 (en) * 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2011158039A1 (en) * 2010-06-17 2011-12-22 Respivert Limited Ureido-pyrazole derivatives for use in the treatment of rhinovirus infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Emerging drugs for respiratory syncytial virus infection;Wieslawa Olszewska and Peter Openshaw;《Expert Opin Emerg Drugs.》;20090630;第14卷(第2期);第207–217页 *

Also Published As

Publication number Publication date
JP2016527259A (ja) 2016-09-08
EP3027608A1 (en) 2016-06-08
CN105683183A (zh) 2016-06-15
KR102297433B1 (ko) 2021-09-02
AU2014298561A8 (en) 2018-06-14
CA2914762A1 (en) 2015-02-05
WO2015014836A1 (en) 2015-02-05
AU2014298561B8 (en) 2018-06-14
EA201690300A1 (ru) 2016-06-30
CA2914762C (en) 2021-11-23
EP3027608B1 (en) 2019-02-20
US20170291891A1 (en) 2017-10-12
AU2014298561B2 (en) 2018-05-31
EA027732B1 (ru) 2017-08-31
US10150761B2 (en) 2018-12-11
ES2724577T3 (es) 2019-09-12
AU2014298561A1 (en) 2015-12-24
JP6397912B2 (ja) 2018-09-26
US20160168124A1 (en) 2016-06-16
KR20160037171A (ko) 2016-04-05

Similar Documents

Publication Publication Date Title
CN108727363B (zh) 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
JP7007290B2 (ja) デングウイルス複製阻害剤としての置換インドール化合物誘導体
CN105283443B (zh) 杂环衍生物及其用途
TWI739783B (zh) 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物
CN111163766A (zh) Ahr抑制剂和其用途
CN106029651A (zh) 用作激酶抑制剂的脲衍生物
CN107531715A (zh) Rsv抗病毒吡唑并‑以及三唑并‑嘧啶化合物
CN106661000A (zh) Egfr抑制剂及其制备和应用
CN104918942A (zh) 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途
CN110753682A (zh) 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
JP2019510027A (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
KR102274755B1 (ko) Ｐｅｒｋ 저해제로서의 신규한 ｎ―（２，３―디히드로―１ｈ―피롤로［２，３―ｂ］피리딘―５―일）―４―퀴나졸린아민 및 ｎ―（２，３―디히드로―１ｈ―인돌―５―일）―４―퀴나졸린아민 유도체
CN107098886B (zh) 含有哌嗪酮的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
CN114423758A (zh) 抗细菌化合物
WO2022063212A1 (zh) 嘧啶基衍生物、其制备方法及其用途
CN103298791B (zh) 病毒聚合酶抑制剂
CN105683183B (zh) 作为rsv抗病毒化合物的经取代的吡啶-哌嗪基类似物
CN105348204B (zh) 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
KR20220136932A (ko) 신규한 디알콕시나프토[2,3-c]퓨란-1(3H)-온 유도체 및 이를 포함하는 호흡기 질환 또는 SARS-CoV-2 감염 질환의 예방 또는 치료용 약제학적 조성물
WO2021115495A1 (zh) 一种小分子含硫杂环化合物
CN110343089A (zh) 苯并咪唑类衍生物及其药学用途
CN119101030A (zh) 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途
JP2024544556A (ja) Ｄｒａｋ２阻害剤およびその製造方法と使用
CN117247380A (zh) 一种噻唑类衍生物及其药物组合物与应用
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180622

CF01 Termination of patent right due to non-payment of annual fee